Are you Dr. Liu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 19 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
101 Dudley St
Providence, RI 02905Phone+1 401-274-1100
Summary
- Dr. Fang Liu, MD is a board certified pathologist in Providence, Rhode Island. She is currently licensed to practice medicine in Rhode Island and Massachusetts. She is affiliated with Saint Vincent Hospital.
Education & Training
Brown UniversityResidency, Pathology-Anatomic and Clinical, 1998 - 2002
Capital University of Medical SciencesClass of 1986
Certifications & Licensure
MA State Medical License 2008 - 2025
RI State Medical License 2002 - 2020- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 1 citationsType of Architecture, Presence of Punctate Necrosis, and Extent of Involvement in Atypical Ductal Hyperplasia Can Predict the Diagnosis of Breast Carcinoma on Excision...Cunxian Zhang, Edmond Y. Wang, Fang Liu, M. Ruhul Quddus, C. James Sung
International Journal of Surgical Pathology. 2021-04-21 - 9 citationsRoutine histologic features in complex atypical hyperplasia can predict the presence of endometrial carcinoma: a clinicopathological study of 222 cases.Cunxian Zhang, Edmond Y. Wang, Fang Liu, C. James Sung, M. Ruhul Quddus
Human Pathology. 2018-03-17 - 89 citationsStat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.Fang Liu, Juxiang Cao, Jinxiang Wu, Kayleigh Sullivan, James Shen
The Journal of Investigative Dermatology. 2013-08-01
Press Mentions
Altered Diversity and Composition of Gut Microbiota in Wilson's DiseaseDecember 11th, 2020
Clinico-Radiological Features and Outcomes in Pregnant Women with COVID-19 Pneumonia Compared with Age-Matched Non-Pregnant WomenJuly 28th, 2020
iCell Gene Therapeutics Presents First-in-Human Data of CLL1-CD33 Compound CAR T in Refractory Acute Myeloid LeukemiaDecember 6th, 2018- Join now to see all
